February 27, 2019

Axial Biotherapeutics Raises $25 Million in Series B Financing

May 02, 2019

Axial Biotherapeutics Presents New Preclinical Data from AB-2004 Program Demonstrating Reduction of Microbiome-Derived Metabolites in Mouse Models with Autism Spectrum Disorder at the International Society for Autism Research (INSAR) 2019 Annual Meeting

May 28, 2019

Axial Biotherapeutics to Participate in Upcoming Conferences in June

May 31, 2019

Axial Biotherapeutics Announces Publication of Preclinical Data Highlighting the Link Between Human Gut Microbiota and Behavioral Symptoms of Autism Spectrum Disorder in Mouse Models

June 20, 2019

Axial Biotherapeutics Announces $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain Axis

July 16, 2019

Axial Biotherapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder

October 11, 2019

Axial Biotherapeutics to Participate in 5th Annual BMO Private Company Showcase

October 18, 2019

Axial Biotherapeutics Presents Preclinical Data on Microbiome – Derived Metabolites Associated with Autism Spectrum Disorder at the Society for Neuroscience 2019 Annual Meeting

November 18, 2019

Axial Biotherapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial Evaluating AB-2004 in Patients with Autism Spectrum Disorder

November 26, 2019

Axial Biotherapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference